Trovagene announces data demonstrating significant synergy of Onvansertib
Trovagene announced preclinical data that evaluated the effect of combining onvansertib with venetoclax in an AML cell model known to be resistant to venetoclax (Venclexta® - AbbVie). This combination demonstrated synergy with a significant decrease in tumor cell viability. April 23, 2019